In breast cancer treatment, the risk of major adverse cardiovascular events (MACE, including coronary artery disease, myocardial infarction, etc.)was significantly reduced in TAM users compared with aromatase inhibitors (AIs)20suggesting a potential cardiovascular benefit. This evidence concerns the gene CYP19A1 and myocardial infarction.